

VIREXX MEDICAL CORP
Form 6-K
June 20, 2006

FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month ended
June 2006

Commission File Number
1-32608

VIREXX MEDICAL CORP.

(Translation of registrant's name into English)

8223 Roper Road NW, Edmonton, Alberta, Canada T6E
6S4

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F [X]

Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): []

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes []

No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
99.1	<u>VIREXX ANNOUNCES THE INITIATION OF A PHASE I CLINICAL STUDY OF HEPAVAXX B</u>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VIREXX MEDICAL CORP.

Date: June 15, 2006

/s/ Scott Langille

Scott Langille
Chief Financial Officer

VIREXX MEDICAL CORP.

Date: June 15, 2006

/s/ Tracy Smith

Tracy Smith
Manager of Finance